Cellectis announces a ten-fold increase in nuclease production capacity in 2011 - Significantly expands potential for technology adoption worldwide

110907_production_EN.pdf

Paris (France), September 7, 2011 – Cellectis (Alternext: ALCLS), the French Genome engineering specialist, has announced that its Nuclease production capacity has increased ten fold in 2011, significantly reducing manufacturing costs. Industrialization of the Nuclease manufacturing gives Cellectis bioresearch, the Genome customization specialist and commercial subsidiary of Cellectis, the potential to supply the technology to approximately 300,000 academic and industrial research laboratories throughout the world. Previously the technology was only used by large industrial groups and laboratories with significant financial resources. In the last three years, Cellectis has invested significantly to increase its production capacities, growing from 20 nucleases produced in 2008 to a capacity of 7,200 units in 2011, a rate that is expected to continue through 2012. The use of nucleases by Cellectis’ initial customers has demonstrated significant advantages over competitive technologies for creating cell lines for high throughput screening, in a number of diverse applications. The use of nucleases may also allow, in a near future, researchers to consider engineering complete genomes for all kinds of species, and for any application. It is revolutionary change for research, which previously required a gene-by-gene approach. “This significant increase in production capacity puts Cellectis’ product offering in a very competitive position for the largest potential Genome engineering customers, at the international level,” said André Choulika, Chairman and CEO of Cellectis. “It represents a major technological step-change that we’ve been targeting for the last 10 years: the high throughput engineering of complete genomes.”